| Literature DB >> 29868452 |
Jesper Hagemeier1, Robert Zivadinov2, Michael G Dwyer3, Paul Polak3, Niels Bergsland4, Bianca Weinstock-Guttman5, Joshua Zalis3, Andreas Deistung6, Jürgen R Reichenbach7, Ferdinand Schweser2.
Abstract
In multiple sclerosis, pathological changes of both tissue iron and myelin occur, yet these factors have not been characterized in a longitudinal fashion using the novel iron- and myelin-sensitive quantitative susceptibility mapping (QSM) MRI technique. We investigated disease-relevant tissue changes associated with myelin loss and iron accumulation in multiple sclerosis deep gray matter (DGM) over two years. One-hundred twenty (120) multiple sclerosis patients and 40 age- and sex-matched healthy controls were included in this prospective study. Written informed consent and local IRB approval were obtained from all participants. Clinical testing and QSM were performed both at baseline and at follow-up. Brain magnetic susceptibility was measured in major DGM structures. Temporal (baseline vs. follow-up) and cross-sectional (multiple sclerosis vs. controls) differences were studied using mixed factorial ANOVA analysis and appropriate t-tests. At either time-point, multiple sclerosis patients had significantly higher susceptibility in the caudate and globus pallidus and lower susceptibility in the thalamus. Over two years, susceptibility increased significantly in the caudate of both controls and multiple sclerosis patients. Inverse thalamic findings among MS patients suggest a multi-phase pathology explained by simultaneous myelin loss and/or iron accumulation followed by iron depletion and/or calcium deposition at later stages.Entities:
Keywords: Iron; Longitudinal study; Multiple sclerosis; QSM; Quantitative susceptibility mapping
Mesh:
Substances:
Year: 2017 PMID: 29868452 PMCID: PMC5984575 DOI: 10.1016/j.nicl.2017.04.008
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Schematic illustration of the QSM processing. Images shown correspond to a 41 years old representative healthy control.
Clinical, demographic, and volumetric MRI data at baseline and change over follow-up.
| Controls | Multiple sclerosis | p-value | |
|---|---|---|---|
| N | 40 | 120 | NA |
| Female, n (%) | 24 (60%) | 81 (67.5%) | 0.387 |
| Age | 43.7 ± 12.3 | 44.2 ± 10.2 | 0.819 |
| RRMS, n (%) | NA | 98 (81.7%) | NA |
| Baseline EDSS, median ± IQR | NA | 2.5 ± (1.5–4.0) | NA |
| Follow-up EDSS, median ± IQR | NA | 3.0 ± (1.5–4.0) | NA |
| Disease duration, years | NA | 12.8 ± 9.4 | NA |
| Baseline relapses in the last year, median ± IQR | NA | 0 ± (0–1) | NA |
| Follow-up relapses in the last year, median ± IQR | NA | 0 ± (0–0) | NA |
| Treated with DMT, n (%) | NA | 103 (85.3%) | NA |
| Follow-up time, years | 1.9 ± 1.2 | 2.1 ± 1.08 | 0.516 |
| Baseline T2 lesion volume, ml | 0.3 ± 0.7 | 13.9 ± 18.1 | < 0.001 |
| Follow-up T2 lesion volume, ml | 0.7 ± 1.7 | 12.6 ± 14.8 | < 0.001 |
| Whole brain volume, ml | 1532.0 ± 76.2 | 1457.8 ± 91.4 | < 0.001 |
| Gray matter volume, ml | 768.0 ± 49.2 | 743.6 ± 54.6 | 0.048 |
| White matter volume, ml | 770.1 ± 43.8 | 723.7 ± 52.5 | < 0.001 |
| Lateral ventricle volume, ml | 33.6 ± 16.2 | 48.1 ± 20.9 | < 0.001 |
| PB-VC | − 0.71 (0.82) | − 1.12 (1.16) | 0.139 |
| PGM-VC | − 1.29 (2.04) | − 1.45 (1.66) | 0.807 |
| PWM-VC | 0.29 (1.54) | 0.50 (2.07) | 0.764 |
| PV-VC | 3.74 (6.11) | 5.12 (7.40) | 0.535 |
Abbreviations: NA = not applicable; RRMS = relapsing-remitting multiple sclerosis; EDSS = Expanded Disability Status Scale; IQR = inter-quartile range; DMT = disease modifying therapy; PB-VC = percent brain volume change, PV-VC = percent ventricle volume change; PGM-VC = percent gray matter volume change; PWM-VC = percent white matter volume change.
Results are based on baseline and percent change data, and are presented as mean ± SD unless otherwise noted. Brain volumes were normalized for head size.
Patients were taking the following disease modifying treatments: interferon beta: 40, natalizumab: 21, glatiramer acetate: 34, combination: 3, other: 5, no therapy: 17. 11 (9.2%) had a change in DMT from baseline to follow-up.
Patients not identified as RRMS were secondary progressive (SP).
Chi-squared test.
Independent Student t-test.
MRI p-values were corrected using false discovery rate resulting in q-values.
Supplementary Fig. 1Magnetic susceptibility of healthy controls plotted against estimated iron concentrations based on analytical equations given in (Hallgren and Sourander, 1958) derived from histochemical iron quantification. Thalamus iron concentration was estimated from Figure 8 in (Hallgren and Sourander, 1958), as described in Supplement 2e. Blue squares: thalamus; green triangles: caudate; tan circles: putamen; and purple crosses: globus pallidus. Dotted line represents the best fit (R2 = 0.91: y = − 26.1 ppb + 6.2 ppb ∙ 100 g/mg ∙ [Fe], where [Fe] is the iron concentration in mg/100 g).
Baseline and follow-up magnetic susceptibility in controls and multiple sclerosis.
| Baseline | Follow-up | Difference (effect size) | q | q | q | ||
|---|---|---|---|---|---|---|---|
| Thalamus | Controls | − 0.4 ± 6.7 | 0.2 ± 6.6 | + 0.6 (g = 0.09) | 0.603 | 0.877 | 0.297 |
| Multiple sclerosis | − 6.1 ± 8.3 | − 6.9 ± 7.8 | − 0.8 (g = 0.10) | 0.251 | |||
| Difference (effect size) | − 5.7 (g = 0.71) | − 7.1 (g = 0.94) | |||||
| q | |||||||
| q | |||||||
| Caudate | Controls | 36.4 ± 8.8 | 38.9 ± 9.9 | + 2.5 (g = 0.27) | 0.628 | ||
| Multiple sclerosis | 44.3 ± 12.8 | 45.9 ± 13.4 | + 1.6 (g = 0.12) | ||||
| Difference (effect size) | + 7.9 (g = 0.66) | + 6.9 (g = 0.54) | |||||
| q | |||||||
| q | |||||||
| Putamen | Controls | 48.7 ± 11.8 | 49.2 ± 11.9 | + 0.5 (g = 0.04) | 0.737 | 0.347 | 0.807 |
| Multiple sclerosis | 51.8 ± 15.6 | 52.8 ± 16.2 | + 1.0 (g = 0.06) | 0.224 | |||
| Difference (effect size) | + 3.1 (g = 0.21) | + 3.6 (g = 0.23) | |||||
| q | 0.469 | 0.403 | |||||
| q | 0.424 | ||||||
| Globus pallidus | Controls | 103.3 ± 15.7 | 102.6 ± 13.6 | − 0.7 (g = 0.05) | 0.807 | 0.877 | 0.611 |
| Multiple sclerosis | 124.2 ± 24.5 | 125.4 ± 25.5 | + 1.2 (g = 0.05) | 0.541 | |||
| Difference (effect size) | + 20.9 (g = 0.92) | + 22.8 (g = 0.98) | |||||
| q | |||||||
| q |
Note: P-values were corrected using false discovery rate resulting in q-values. Between-subject q-values are presented below descriptive results, while within-subject q-values are presented to the right of descriptive results. Results described as mean ± SD, susceptibility is stated in ppb. Effect sizes were computed using Hedge's g.
q-value of the within group difference between baseline and follow-up (paired t-test).
q-value of the difference between controls and multiple sclerosis (independent t-test).
Main effect of time (mixed factorial ANOVA).
q-value of the interaction effect of time by disease (mixed factorial ANOVA).
Main effect of disease (mixed factorial ANOVA).
Statistical significance of caudate magnetic susceptibility among multiple sclerosis patients was lost (p > 0.05) when adjusting for caudate volume. Other structures were unaffected.
Fig. 2Susceptibility change trajectories as a function of age for the thalamus, caudate, putamen, and globus pallidus. The left column depicts controls while the right column depicts multiple sclerosis patients. Gray circles indicate baseline; black circles indicate follow-up. The dashed linear fits represent the mean change in susceptibility as a function of age. Regression coefficients are as follows: controls: thalamus = − 0.107 ppb/years ∙ [age] + 4.713 ppb, caudate = 0.363 ppb/years ∙ [age] + 21.305 ppb, putamen = 0.501 ppb/years ∙ [age] + 26.310 ppb, globus pallidus = 0.416 ppb/years ∙ [age] + 84.117 ppb; multiple sclerosis: thalamus = − 0.227 ppb/years ∙ [age] + 3.834 ppb, caudate = 0.480 ppb/years ∙ [age] + 23.157 ppb, putamen = 0.501 ppb/years ∙ [age] + 29.447 ppb, globus pallidus = 0.629 ppb/years ∙ [age] + 96.024 ppb.
Fig. 3Trajectories of individual normalized volumes as a function of age for the thalamus, caudate, putamen, and globus pallidus. The left column depicts controls while the right-hand side depicts multiple sclerosis patients. Gray circles indicate baseline; black circles indicate follow-up. The dashed linear fits represent the mean change in volume as a function of age. Regression coefficients are as follows: controls: thalamus = − 0.066 ml/years ∙ [age] + 23.647 ml, caudate = − 0.037 ml/years ∙ [age] + 10.738 ml, putamen = − 0.036 ml/years ∙ [age] + 14.46 ml, globus pallidus = 0.005 ml/years ∙ [age] + 4.425 ml; multiple sclerosis: thalamus = − 0.080 ml/years ∙ [age] + 22.270 ml, caudate = − 0.041 ml/years ∙ [age] + 10.266 ml, putamen = − 0.044 ml/years ∙ [age] + 13.991 ml, globus pallidus = − 0.001 ml/years ∙ [age] + 4.291 ml.
Supplementary Fig. 2Monte-Carlo simulation of expected age-dependent group-average trajectories of susceptibility (a, c) and R2* (b, d) in the thalamus. The iron depletion model is shown in the top row (a, b), the calcium model in the bottom row (c, d). Straight red lines represent the simulated cross-sectional group-control differences. Straight and dashed black lines are the simulated normal and MS group values. Data points with error bars (95% CI; estimated from reported standard deviations/errors) represent values found at both time points in the present study and previously reported cross-sectional differences in Al-Radaideh et al. (2013) (A), Langkammer et al. (2013) (B), Rudko et al. (2014) (C), and Khalil et al. (2015) (D). Details of the simulations are reported in Supplement 3.